Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
Go back to Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 469.46 +2.67 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $466.79 | 52 Week High | $134.71 | |||
| Open | $469.67 | 52 Week Low | $73.31 | |||
| Day High | $470.82 | P/E | N/A | |||
| Day Low | $463.76 | EPS | $-1.98 | |||
| Volume | 558,652 | |||||
